Category: Sponsors

Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule

by Todd | Feb 16, 2018 | General, Pharma & Biotech | • Nemus Bioscience Receives $1,750,000 Private Placement to Help Advance Innovative Bio-engineered Cannabinoid Pipeline Costa Mesa, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) — NEMUS Bioscience, Inc. (OTCQB: NMUS, “Nemus”) is pleased to announce that today it received $1,750,000 in the final closing of the private placement from Emerald Health Sciences Inc. (“Emerald”) and additional investors in accordance with a previously executed securities purchase agreement, which is $750,000 greater than previously announced. Emerald purchased 15,000,000 shares of common stock at $0.10 per share and warrants to purchase a further 20,400,000 shares of common stock at $0.10 per share. Emerald holds a majority of Nemus’ common shares on a fully converted basis. “Nemus brings a robust cannabinoid developmental pipeline into Emerald’s family of life science companies,” noted Dr. Avtar Dhillon, CEO and Chairman of Emerald Health Sciences. “Emerald stands with Nemus and their discovery partner, the University of Mississippi, to now advance Nemus’ portfolio of proprietary biosynthetic cannabinoid molecules into the next pivotal stages of development.” “We are delighted with Emerald’s commitment to advance Nemus’ pipeline, particularly as we now advance multiple ophthalmology targets including animal studies of our analog of cannabidiol (CBD) to potentially treat and manage dry eye syndrome, as well as moving toward human studies of our prodrug of THC to treat glaucoma. Both therapeutic targets...

Read More

Canopy Growth successful in bid to operate private retail stores in Manitoba

by Todd | Feb 16, 2018 | CULTIVATION & RETAIL, General | SMITHS FALLS, ON, Feb. 16, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (“Canopy Growth” or the “Company”) is pleased to announce that it has been conditionally selected by the Government of Manitoba to operate cannabis retail stores in the province after a rigorous and highly competitive RFP process. Canopy Growth, along with its partner Delta 9, is one of four successful candidates chosen to operate a number of retail locations throughout the province. Further details on locations and store quantities will follow as the RFP process is finalized. Once official, this will mark Canopy Growth’s second provincial retail agreement after previously announcing plans to apply to operate four retail stores in the Province of Newfoundland & Labrador. To date, four provinces in Canada have put forward their retail and supply frameworks including New Brunswick, Newfoundland & Labrador, and Prince Edward Island; and all of them have chosen Canopy Growth as a trusted partner and supplier. Just this week, Canopy Growth also entered into a Letter of Intent (LOI) with the province of Quebec to supply up to 12,000 kg of cannabis in that province annually. “I would like to commend the Government of Manitoba on choosing a competitive retail model that offers access to a variety of new and existing cannabis brands to Manitobans,” said Mark...

Read More

CannaRoyalty Enters into Strategic Partnership with Leading Premium Craft Cannabis Cultivator, FloraCalĀ® Farms, to Develop and Sell Branded Cannabis Products

by Todd | Feb 15, 2018 | General, Investments and M&A | • Strategic Partnership to collaborate on the construction and build-out of a 20,000 square foot craft cultivation expansion in CannaRoyalty’s existing California facility • CannaRoyalty to obtain exclusive global rights to license FloraCal’s full IP portfolio, inclusive of brand, outside of California • Strategic Partnership to collaborate on new lines of ultra-premium cannabis flower products Ottawa, Canada – February 15, 2018 – CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty” or the “Company”), an active investor and operator in the legal cannabis industry, announced today that it has signed a binding Letter of Intent (the “LOI”) with FloraCal® Farms (“FloraCal”) to enter into a strategic partnership regarding craft premium cannabis flower production, branding and sales, and other strategic initiatives (the “Strategic Partnership”). The LOI also contemplates the receipt by CannaRoyalty of the exclusive global rights to license FloraCal’s full Intellectual Property (“IP”) portfolio, inclusive of brand, outside of California. FloraCal is a 100% family owned and operated cultivator in Northern California that handcrafts, brands and packages small batches of ultra-premium cannabis flower, with an average selling price of over US$17 per gram. FloraCal’s products are currently available in over 210 dispensaries in California through CannaRoyalty investee River Distribution (“River”). The Company and FloraCal will jointly execute a purpose-built expansion into CannaRoyalty’s existing 20,000 square foot facility in Sonoma...

Read More

Isodiol International Inc. Signs Definitive Agreement to Acquire 100% Of Canadian National Pharma Group INC.

by Todd | Feb 15, 2018 | General, Hemp, Pharma & Biotech | February 15, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma Group Inc. (CN Pharma), a pharmaceutical manufacturing company. Isodiol previously announced on Dec. 6th, 2017 the agreement to acquire an initial stake representing 25% equity of CN Pharma. The company is now pleased to purchase the remaining 75% equity and is excited to establish CN Pharma as a wholly owned subsidiary. Once approved by Health Canada, CN Pharma will be licensed to process and manufacture controlled substances, handle all cannabis and hemp derivatives, import and export oils and isolates, prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug development. “This is a strategic acquisition for Isodiol, and we intend to expand our capacity in Canada in a significant way,” said Marcos Agramont, CEO of Isodiol. “With this new and up and coming facility, Isodiol will be able to refine and isolate the CBD molecule to a pharmaceutical-grade purity of 99.5% + as well other Cannabinoid derivatives. As a certified Licensed Dealer, Isodiol will continue to establish...

Read More

THC Announces Letter of Intent to Purchase Farm and Greenhouses in the Niagara area in the Province of Ontario

by Todd | Feb 15, 2018 | CULTIVATION & RETAIL, General | Vancouver, British Columbia – (February 15, 2018) Canada’s largest supplier of legal Cannabis Genetics, THC BioMed Intl Ltd. (CSE: THC), (“THC” or the “Company”), announces that it has entered into a Letter of Intent to purchase a Farm and Greenhouses on approximately eight and a half acres in the Niagara region, Ontario. THC previously announced its intention to pursue this opportunity on December 20, 2017. THC intends to add this new property in Ontario to its licensed facilities in B.C. for the licensed production of cannabis. The new property has approximately seven acres of growing space, including seventy thousand square feet in the greenhouses. Irrigation equipment and all equipment and supplies necessary for the operation of the greenhouses are included in the purchase. THC is also pleased to announce that one of the Vendors of the property has agreed to stay on as a consultant, bringing his 32 years expertise as a farmer in this region to bear for THC’s crops. There is a farmhouse on the property, which the Vendors intend to rent from THC at market rates. The parties intend to enter into a formal asset purchase agreement. The completion of the acquisition is subject to standard real estate purchase conditions and the approval of the CSE. “THC is excited to be expanding into Ontario,”...

Read More

Solaris Nutraceuticals Receives AUD$2,500,000 Grant from Federal Department of Innovation, Industry & Science

VANCOUVER, British Columbia , Feb 15, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (“MYM”) In response to an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant and its strategic partners PUF Ventures Inc. (CSE: PUF) are pleased to announce the Australia based Solaris Nutraceuticals Pty Ltd, which is building the largest medical cannabis greenhouse southern hemisphere, has been awarded a $AUD2,500,000 Regional Jobs Investment Program (RJIP) grant, through Federal Department of Innovation, Industry & Science, “We are co-investing with Solaris Nutraceuticals to make sure it (the medicinal cannabis facility) happens,” said Kevin Hogan, Australian Member of Parliament. “Up to 280 jobs will be there one day providing this great new product that is needed by our community. We look forward to having the largest medicinal cannabis facility in the Southern Hemisphere soon in Casino.” “We are very honoured to be awarded this Federal Grant towards the construction of our 1,200,000 sq. f.t greenhouse,” said Michael Horsfall, Co-founder and CEO of Solaris Nutraceuticals. “We have been overwhelmed with the generous support we have received from all levels of Government. We are working hard to deliver this project. We expect to create upwards of 300 to 500 direct and indirect jobs in the Northern Rivers Region from our greenhouse project. This will provide a significant boost to the local economy” The new facility will be Australia’s...

Read More